Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission. These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality. Social isolation strategies have been implemented worldwide with the aim of reducing hospital pressure. Among therapeutic strategies, the use of immunomodulating drugs, to improve prognosis, seems promising. Particularly, since pneumonia and ARDS are associated with a cytokine storm, drugs belonging to therapeutic classes as anti-IL-6, anti-TNF, and JAK inhibitors are currently studied. In this article, we discuss the potential advantages of the most promising pharmacological approaches.
【저자키워드】 COVID-19, SARS-CoV-2, Cytokines, interleukin-6, tumor necrosis factor, molecular targeted therapy, Janus kinases, 【초록키워드】 ARDS, Cytokine storm, intensive care, Prognosis, Pneumonia, hospital, drug, therapeutic, Therapeutic strategies, Isolation, Complication, Admission, Care, JAK inhibitor, acute respiratory distress, Healthcare systems, anti-TNF, approaches, syndrome, increased mortality, pharmacological, anti-IL-6, immunomodulating drugs, IMPROVE, include, condition, reducing, detrimental effect, 【제목키워드】 Cytokine storm, Pneumonia, acute respiratory distress, COVID-19 patient, syndrome, pharmacological, approach,